Combining Radiotherapy and Immunotherapy for Cancer Treatment
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Thoracic Oncology".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 116
Special Issue Editor
Special Issue Information
Dear Colleagues,
Radiation therapy and immunotherapy are both pivotal cancer treatment modalities. However, their relationship with each other is a complex one. On the one hand, radiation has immunomodulatory effects, improving the immunogenicity of tumors, priming the immune system, and setting the stage for effective immunotherapy. On the other hand, radiation can lead to profound lymphopenia, depleting the body of lymphocytes that are the soldiers with which immunotherapy wages its battle against cancer.
In this Special Issue, original research articles, reviews, and perspectives are welcome regarding the topic of combining the double-edged sword of radiation therapy and immunotherapy, with the aim of stimulating discussion and engendering novel ideas about how to optimize treatment outcomes for our patients.
Dr. Yufei Liu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- radiation oncology
- immunotherapy
- immunomodulation
- immune checkpoint inhibitors
- abscopal effect
- stereotactic body ra-diation therapy
- antibody–drug conjugate
- CAR-T cell therapy
- tumor-infiltrating lymphocytes
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
